Literature DB >> 24617953

Meta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy.

Guohong Gao1, Jinhui Dai, Yifeng Qian, Fei Ma.   

Abstract

A meta-analysis was performed to evaluate the efficacy of methylprednisolone pulse therapy for Graves' ophthalmopathy. Eight studies involving 376 patients were included. A higher effective rate was found for patients treated with intravenous glucocorticoids (IVGC) over oral glucocorticoids (OGC) (risk ratio [RR] = 1.48; 95% confidence interval [CI] = 1.18-1.86). The combined IVGC and orbital radiotherapy (OR) was markedly more effective than OGC+OR (RR = 1.40; 95% CI = 1.11-1.77). IVGC resulted in an obvious reduction of clinical activity score (CAS) compared with OGC, with a weighted mean difference (WMD) of 0.86 (95% CI = 0.53-1.18). The WMD for the reduction of the CAS between IVGC+OR and OGC+OR was 0.66 (95% CI = 0.30-1.02). IVGC is an effective treatment and cause fewer adverse events. Limiting the total cumulative dose of methylprednisolone, careful patient selection and monitoring the condition of patients during treatment are necessary.
© 2014 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  Graves' ophthalmopathy; drug therapy; glucocorticoid; meta-analysis

Mesh:

Substances:

Year:  2014        PMID: 24617953     DOI: 10.1111/ceo.12317

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  13 in total

Review 1.  Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.

Authors:  Mariacarla Moleti; Giuseppe Giuffrida; Giacomo Sturniolo; Giovanni Squadrito; Alfredo Campennì; Silvia Morelli; Efisio Puxeddu; Eleonora Sisti; Francesco Trimarchi; Francesco Vermiglio; Michele Marinò
Journal:  Endocrine       Date:  2016-03-22       Impact factor: 3.633

2.  The effects of bone metabolism in different methylprednisolone pulse treatments for Graves' ophthalmopathy.

Authors:  Yong-Xin Hu; Ren-Dong Zheng; Yao-Fu Fan; Li Sun; Xin Hu; Chao Liu
Journal:  Exp Ther Med       Date:  2019-11-08       Impact factor: 2.447

Review 3.  Current and Emerging Treatment Strategies for Graves' Orbitopathy.

Authors:  Natalia Genere; Marius N Stan
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 4.  Ocular surface disease in thyroid eye disease: A narrative review.

Authors:  Harkaran S Rana; Sruti S Akella; Carson E Clabeaux; Zachary P Skurski; Vinay K Aakalu
Journal:  Ocul Surf       Date:  2022-02-12       Impact factor: 6.268

Review 5.  Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review.

Authors:  Xueting Li; Senmao Li; Wanlin Fan; Alexander C Rokohl; Sitong Ju; Xiaojun Ju; Yongwei Guo; Ludwig M Heindl
Journal:  Int Ophthalmol       Date:  2022-10-22       Impact factor: 2.029

6.  Methotrexate as a Corticosteroid-Sparing Agent for Thyroid Eye Disease.

Authors:  Erick Rivera-Grana; Phoebe Lin; Eric B Suhler; James T Rosenbaum
Journal:  J Clin Exp Ophthalmol       Date:  2015-04-27

7.  Common Immunosuppressive Monotherapy for Graves' Ophthalmopathy: A Meta-Analysis.

Authors:  Pei Mou; Li-Hong Jiang; Yun Zhang; Yu-Zhen Li; Heng Lou; Cheng-Cheng Zeng; Qiu-Hong Wang; Jin-Wei Cheng; Rui-Li Wei
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

Review 8.  Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures.

Authors:  Samia Al Jabri; Jamie Kirkham; Fiona J Rowe
Journal:  BMC Ophthalmol       Date:  2019-02-08       Impact factor: 2.209

9.  Corticosteroids for Graves' Ophthalmopathy: Systematic Review and Meta-Analysis.

Authors:  Xiaofang Tu; Yan Dong; Hongmei Zhang; Qing Su
Journal:  Biomed Res Int       Date:  2018-11-22       Impact factor: 3.411

Review 10.  Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis.

Authors:  Nuo Xu; Yi Cui; Tianlu Xie; Mi Zheng
Journal:  J Ophthalmol       Date:  2018-12-12       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.